Scott L. Friedman | Academic Influence

Why Is Scott L. Friedman Influential?

According to Wikipedia, Scott L. Friedman is an American scientist, professor and physician who works in the field of hepatology. Friedman has conducted pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, by characterizing the key fibrogenic cell type, the hepatic stellate cell His laboratory has also discovered a novel tumor suppressor gene, KLF6 that is inactivated in a number of human cancers including primary liver cancer. Friedman is the Fishberg Professor of Medicine, and Chief of the Division of Liver Diseases, Mount Sinai School of Medicine in New York. Friedman has two children, a son, Leor Friedman, and a daughter, Yael Friedman.

(See a Problem?)

Scott L. Friedman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2869)
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. (2008) (2331)
Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* (2000) (2073)
Liver fibrosis -- from bench to bedside. (2003) (1638)
Mechanisms of hepatic fibrogenesis. (2008) (1546)
Mechanisms of NAFLD development and therapeutic strategies (2018) (1536)
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies (1993) (1476)
Mechanisms of hepatic stellate cell activation (2017) (1304)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. (2015) (1293)
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. (2008) (1148)
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs (1998) (889)
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. (2009) (869)
Pathogenesis of liver fibrosis. (2011) (827)
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis (2004) (822)
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. (1985) (799)
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. (2017) (676)
Pathobiology of liver fibrosis: a translational success story (2015) (673)
Pivotal role of mTOR signaling in hepatocellular carcinoma. (2008) (668)
Hepatic stellate cells and liver fibrosis. (2013) (651)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) (641)
Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma (2007) (641)
Hepatic stellate cells as key target in liver fibrosis. (2017) (610)
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. (2013) (574)
Therapy for Fibrotic Diseases: Nearing the Starting Line (2013) (571)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. (2008) (552)
Genomics and signaling pathways in hepatocellular carcinoma. (2007) (547)
Evolving challenges in hepatic fibrosis (2010) (525)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. (2017) (508)
Apoptosis: The nexus of liver injury and fibrosis (2004) (507)
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. (2012) (482)
Hepatic fibrosis: Concept to treatment. (2015) (480)
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications (2004) (464)
KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer (2001) (459)
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis (2018) (457)
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis (2010) (457)
Activation of hepatic stellate cells--a key issue in liver fibrosis. (2002) (442)
The Movement of Aquatic Mercury Through Terrestrial Food Webs (2008) (396)
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. (2017) (389)
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. (1989) (385)
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. (2006) (381)
Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice (2002) (380)
Mechanisms of hepatic fibrogenesis. (2011) (373)
Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. (1993) (373)
Reversal of hepatic fibrosis — Fact or fantasy? (2006) (370)
Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic (2003) (370)
Functions of autophagy in normal and diseased liver (2013) (358)
Cytokines and fibrogenesis. (1999) (356)
Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. (1992) (346)
Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. (1989) (335)
Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. (1987) (332)
Fibrosis‐dependent mechanisms of hepatocarcinogenesis (2012) (328)
Hepatic fibrosis -- overview. (2008) (322)
Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy (1999) (319)
Hepatic stellate cells. (1996) (319)
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C (2007) (305)
Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. (1994) (291)
Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture (1992) (288)
Senolytic CAR T cells reverse senescence-associated pathologies (2020) (283)
Mechanisms and disease consequences of nonalcoholic fatty liver disease (2021) (272)
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop (2015) (272)
An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. (2000) (266)
Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats (2007) (261)
Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1–derived reactive oxygen species (2002) (258)
Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. (2006) (256)
Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. (1993) (253)
Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. (1998) (250)
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo (2006) (248)
Molecular regulation of hepatic fibrogenesis. (1998) (248)
Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. (1998) (247)
DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. (2001) (247)
Expression and role of Bcl‐xL in human hepatocellular carcinomas (2001) (244)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (240)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (237)
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis (2010) (235)
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. (2018) (228)
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. (2004) (224)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. (2009) (223)
Activated stellate cells express the TRAIL receptor‐2/death receptor‐5 and undergo TRAIL‐mediated apoptosis (2003) (222)
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis (2016) (222)
Discoidin Domain Receptor 2 Regulates Fibroblast Proliferation and Migration through the Extracellular Matrix in Association with Transcriptional Activation of Matrix Metalloproteinase-2* (2002) (221)
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. (2005) (220)
Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. (2000) (218)
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. (2011) (218)
Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. (1992) (214)
Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis (2006) (214)
Experimental models of hepatocellular carcinoma. (2008) (207)
Functional linkage of cirrhosis‐predictive single nucleotide polymorphisms of toll‐like receptor 4 to hepatic stellate cell responses (2009) (205)
Cellular sources of collagen and regulation of collagen production in liver. (1990) (194)
Hepatic fibrosis--role of hepatic stellate cell activation. (2002) (193)
Proangiogenic role of tumor‐activated hepatic stellate cells in experimental melanoma metastasis (2003) (192)
Hepatic fibrosis. Pathogenesis and principles of therapy. (2001) (192)
Innate immunity in alcoholic liver disease. (2011) (187)
Is liver fibrosis reversible? (2001) (186)
Cytochrome P450 2E1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells* (2002) (183)
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. (2008) (183)
Current status of novel antifibrotic therapies in patients with chronic liver disease (2011) (182)
Inhibition of rat hepatic lipocyte activation in culture by interferon‐γ (1992) (181)
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. (2013) (180)
Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. (2002) (180)
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. (2012) (180)
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. (2002) (179)
Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. (2013) (178)
Scraping fibrosis: Expressway to the core of fibrosis (2011) (177)
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. (2004) (175)
CYP2E1‐mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells (1999) (175)
Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States—A Single‐Center Experience (2016) (174)
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid‐induced liver injury in superobese patients with nonalcoholic steatohepatitis (2013) (173)
Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. (1989) (171)
Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease (2013) (169)
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. (2005) (168)
Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats (2008) (166)
Krüppel-like Factor-6 Promotes Preadipocyte Differentiation through Histone Deacetylase 3-dependent Repression of DLK1* (2005) (162)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. (2016) (161)
Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1 (2004) (155)
Frequent inactivation of the tumor suppressor Kruppel‐like factor 6 (KLF6) in hepatocellular carcinoma (2004) (152)
Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. (1988) (150)
Detection of novel biomarkers of liver cirrhosis by proteomic analysis (2009) (146)
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. (2016) (145)
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. (2009) (145)
Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) (142)
Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. (1994) (140)
Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation (2010) (139)
Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. (2011) (138)
Mechanisms and therapy of hepatic fibrosis: Report of the AASLD single topic basic research conference (2000) (138)
Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. (1992) (137)
Immunolocalization of laminin in normal rat liver and biosynthesis of laminin by hepatic lipocytes in primary culture. (1988) (137)
Transcriptional activation of urokinase by the Krüppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. (2000) (134)
Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats (2006) (133)
Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. (2006) (133)
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis (2008) (133)
Transplantation trends in primary biliary cirrhosis. (2007) (132)
Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing (1998) (131)
The Role of Chemokines in Acute Liver Injury (2012) (131)
Discoidin Domain Receptor 2 Interacts with Src and Shc following Its Activation by Type I Collagen* (2002) (129)
Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. (2001) (129)
Connective tissue biology and hepatic fibrosis: Report of a conference (1990) (125)
PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis (2016) (124)
Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs (1997) (124)
Ethanol and Arachidonic Acid Increase α2(I) Collagen Expression in Rat Hepatic Stellate Cells Overexpressing Cytochrome P450 2E1 (2000) (123)
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. (2006) (123)
β-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis (2015) (121)
Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. (1994) (120)
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? (2014) (120)
Stellate cells: A moving target in hepatic fibrogenesis (2004) (119)
Molecular basis of hepatic fibrosis (2003) (118)
A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice (2013) (118)
Dendritic cell regulation of carbon tetrachloride–induced murine liver fibrosis regression (2012) (116)
Mechanism of retarded liver regeneration in plasminogen activator‐deficient mice: Impaired activation of hepatocyte growth factor after Fas‐mediated massive hepatic apoptosis (2001) (114)
Formation of extracellular matrix in normal rat liver: lipocytes as a major source of proteoglycan. (1988) (114)
Gene-expression signature of vascular invasion in hepatocellular carcinoma. (2011) (113)
Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. (2019) (113)
Amelioration of hepatic fibrosis by NK cell activation (2010) (112)
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. (2008) (110)
Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination (2006) (109)
Stellate cell activation in alcoholic fibrosis--an overview. (1999) (108)
Hepatic fibrosis 2006: Report of the third AASLD Single Topic Conference (2007) (108)
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. (2012) (106)
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. (2010) (106)
Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF. (1993) (105)
BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. (2006) (104)
Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease (2009) (100)
Current Diagnosis & Treatment in Gastroenterology (2002) (100)
NRBF2 Regulates Autophagy and Prevents Liver Injury by Modulating Atg14L-Linked Phosphatidylinositol-3 Kinase III Activity (2014) (100)
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. (2008) (99)
Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. (2005) (98)
A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection (2015) (96)
Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. (2005) (96)
Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis. (2005) (95)
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science (2017) (92)
Cellular basis of hepatic fibrosis and its role in inflammation and cancer. (2013) (91)
Is liver fibrosis reversible (2001) (90)
Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6 (2004) (87)
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. (2007) (85)
Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap (2018) (85)
IL-17A Enhances the Expression of Profibrotic Genes through Upregulation of the TGF-β Receptor on Hepatic Stellate Cells in a JNK-Dependent Manner (2014) (85)
Retinoids in cancer chemoprevention. (2004) (85)
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. (2009) (84)
Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation‐related protein (ADRP) (2010) (83)
Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. (2005) (82)
Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. (1999) (82)
Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. (2015) (82)
Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma (2007) (81)
In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma (2007) (81)
Lhx2-/- mice develop liver fibrosis. (2004) (80)
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma (2018) (79)
Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer (2014) (78)
Autophagy fuels tissue fibrogenesis (2012) (78)
Advances in antifibrotic therapy (2008) (78)
Transcriptional regulation in hepatic stellate cells. (2001) (78)
Antifibrotic Therapies: Where Are We Now? (2016) (77)
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor‐β and vascular endothelial growth factor signalling (2013) (77)
Emerging and disease-specific mechanisms of hepatic stellate cell activation. (2015) (76)
E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor (2006) (74)
Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258 (2009) (72)
The Krüppel‐like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact (2000) (70)
Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma (2002) (69)
The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy (2016) (67)
Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling (2011) (66)
CD11b+ Gr1+ bone marrow cells ameliorate liver fibrosis by producing interleukin‐10 in mice (2012) (66)
Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. (2003) (65)
The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells. (2020) (65)
β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. (2014) (64)
Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I Expression (2011) (64)
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration (2014) (64)
Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis (2011) (63)
Antifibrotic Agents for Liver Disease (2006) (63)
The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation (2016) (62)
Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. (2004) (61)
Prostaglandin E2 inhibits transforming growth factor β1-mediated induction of collagen α1(I) in hepatic stellate cells (2004) (60)
Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα(-/-) mice. (2014) (60)
Early genes induced in hepatic stellate cells during wound healing. (1997) (59)
Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. (2010) (59)
Glucokinase links Krüppel‐like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease (2012) (59)
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014 (2015) (59)
Molecular mechanisms of hepatic fibrosis and principles of therapy (1997) (58)
Hepatic Fibrosis: Emerging Therapies (2015) (58)
Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. (2013) (58)
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. (2013) (56)
The virtuosity of hepatic stellate cells. (1999) (56)
Evaluation of fibrosis and hepatitis C. (1999) (56)
Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. (2005) (56)
Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo (2012) (56)
Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. (2014) (55)
Hepatocyte Growth Factor Enhances Alternative Splicing of the Krüppel-like Factor 6 (KLF6) Tumor Suppressor to Promote Growth through SRSF1 (2012) (55)
Loss of discoidin domain receptor 2 promotes hepatic fibrosis after chronic carbon tetrachloride through altered paracrine interactions between hepatic stellate cells and liver-associated macrophages. (2011) (54)
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH (2013) (54)
Functional role of the KLF6 tumour suppressor gene in gastric cancer. (2009) (53)
Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non‐alcoholic steatohepatitis (2017) (53)
Treatment of hepatic fibrosis: Almost there (2003) (53)
Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. (2006) (52)
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis (2020) (52)
Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection (2016) (52)
Vascular Injury Triggers Krüppel-Like Factor 6 Mobilization and Cooperation With Specificity Protein 1 to Promote Endothelial Activation Through Upregulation of the Activin Receptor-Like Kinase 1 Gene (2013) (52)
The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. (2015) (50)
Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. (2008) (50)
Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. (2011) (50)
Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. (2004) (50)
Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention (2016) (50)
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC (2020) (50)
Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells (1997) (50)
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. (2013) (50)
Parenchymal and nonparenchymal cell interactions in the liver. (1993) (48)
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. (2019) (48)
Genomics and proteomics in liver fibrosis and cirrhosis (2012) (47)
Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury (2016) (47)
Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH (2017) (47)
p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. (1997) (47)
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. (2017) (47)
Synergistic induction of apoptosis by acyclic retinoid and interferon‐β in human hepatocellular carcinoma cells (2002) (46)
Hepatic fibrogenesis. (2018) (46)
Krüppel cripples prostate cancer: KLF6 progress and prospects. (2003) (46)
Transcriptional regulation of stellate cell activation (2006) (46)
Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. (2016) (45)
p38‐MAPK‐ and caspase‐3‐mediated superoxide‐induced apoptosis of rat hepatic stellate cells: Reversal by retinoic acid (2009) (45)
Embryonic expression of Krüppel-like factor 6 in neural and non-neural tissues (2001) (44)
Prevention of Rat Hepatocarcinogenesis by Acyclic Retinoid Is Accompanied by Reduction in Emergence of Both TGF-α-Expressing Oval-Like Cells and Activated Hepatic Stellate Cells (2005) (43)
Carcinogen‐induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation (2011) (43)
TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. (2009) (42)
Fibrogenic cell reversion underlies fibrosis regression in liver (2012) (42)
Central Role of Conventional Dendritic Cells in Regulation of Bone Marrow Release and Survival of Neutrophils (2014) (42)
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease ( NAFLD ) , Non-alcoholic Steatohepatitis ( NASH ) and Associated Fibrosis (2017) (42)
Why do so many NASH trials fail? (2020) (41)
Genetic Characteristics of the Human Hepatic Stellate Cell Line LX-2 (2013) (41)
Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. (2021) (40)
Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases (2017) (40)
Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. (2004) (40)
Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. (2015) (39)
Activation of rat hepatic stellate cells leads to loss of glutathion S‐transferases and their enzymatic activity against products of oxidative stress (1999) (39)
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing (2012) (39)
Programmed cell death‐1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma (2017) (39)
New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. (2019) (39)
Improved specificity of myoglobin plus carbonic anhydrase assay versus that of creatine kinase-MB for early diagnosis of acute myocardial infarction. (1996) (38)
KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma (2007) (38)
Reduced hepatic stellate cell expression of kruppel‐like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury (2013) (37)
Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). (2004) (36)
Closing in on the signals of hepatic fibrosis. (1997) (36)
GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21 (2013) (36)
Anti‐fibrotic activity and enhanced interleukin‐6 production by hepatic stellate cells in response to imatinib mesylate (2012) (36)
SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF. (2011) (35)
E3 Ubiquitin Ligase Synoviolin Is Involved in Liver Fibrogenesis (2010) (34)
CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. (2016) (34)
The RING Finger Protein, RNF8, Interacts with Retinoid X Receptor α and Enhances Its Transcription-stimulating Activity* (2004) (34)
PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling (2009) (34)
Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury (2019) (34)
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future (2021) (34)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Epithelial Xbp1 Is Required for Cellular Proliferation and Differentiation during Mammary Gland Development (2015) (32)
Reversibility of hepatic fibrosis and cirrhosis—is it all hype? (2007) (32)
Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1 (2010) (32)
A DDX5 S480A Polymorphism Is Associated with Increased Transcription of Fibrogenic Genes in Hepatic Stellate Cells* (2009) (32)
Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. (2010) (31)
KLF6 degradation after apoptotic DNA damage (2006) (31)
Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells (2004) (31)
Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells (2009) (31)
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma (2021) (30)
DDR 2 receptor promotes MMP-2 – mediated proliferation and invasion by hepatic stellate cells (2001) (30)
Fibrosis in the liver: acute protection and chronic disease. (2010) (30)
Hepatic stellate cell nomenclature. (1996) (30)
Acetaldehyde and alcoholic fibrogenesis: Fuel to the fire, but not the spark (1990) (30)
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. (2021) (30)
Liver fibrosis: from mechanisms to treatment. (2007) (29)
A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis (2011) (29)
Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies. (2008) (29)
Hepatic lipocytes: a major target for endothelin-1. (1995) (28)
Cellular Networks in Hepatic Fibrosis (1998) (28)
Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. (2007) (28)
The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination (2016) (28)
Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury (2015) (27)
Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. (2016) (27)
Cytoskeleton of liver perisinusoidal cells (lipocytes) in normal and pathological conditions. (1992) (27)
Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes (2006) (27)
Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C (2011) (27)
Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature (2011) (26)
Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study (2016) (26)
Neoplasms of the gastrointestinal tract and hepatobiliary system in acquired immunodeficiency syndrome. (1992) (25)
CARDIOVASCULAR TOLERANCE IN UNSEDATED UPPER GASTROINTESTINAL ENDOSCOPY: PROSPECTIVE RANDOMIZED COMPARISON BETWEEN TRANSNASAL AND CONVENTIONAL ORAL PROCEDURES (2006) (25)
Hepatic fibrosis: A convergent response to liver injury that is reversible. (2020) (25)
An improved, simple nest-box trap (2008) (25)
The biology of Krüppel-like factors (2009) (25)
Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells (2017) (25)
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene (2010) (25)
Hepatic fibrosis (2009) (25)
Liver Injury in Hospitalized Patients with COVID-19 Correlates with Hyper Inflammatory Response and Elevated IL-6. (2020) (25)
High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells. (2012) (25)
Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation (2011) (24)
Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. (2015) (24)
SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis (2017) (24)
Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis (2006) (24)
Fibrosis regression after eradication of hepatitis C virus - from bench to bedside. (2021) (24)
A deer in the headlights: BAMBI meets liver fibrosis (2007) (23)
Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis (2008) (23)
LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis (2014) (23)
Transcriptional Activation of Transforming Growth Factor β1 and Its Receptors by the Kruppel-like Factor Zf9/Core Promoter-binding Protein and Sp1 (1998) (22)
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis (2021) (22)
Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. (2006) (22)
Cellular sources of glutathione S-transferase P in primary cultured rat hepatocytes: localization by in situ hybridization. (1994) (22)
Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades (2019) (21)
CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. (2013) (21)
Isolation and Culture of Hepatic Nonparenchymal Cells (1993) (21)
The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis (2007) (21)
Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. (2008) (20)
Cyclin-Dependent Kinase Inhibition by the KLF 6 Tumor Suppressor Protein through Interaction with Cyclin D 1 (2004) (20)
Future trends in hepatology: Challenges and opportunities (2008) (20)
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study (2018) (19)
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury (2017) (19)
Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. (2020) (19)
Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells (2016) (18)
Mechanisms of Liver Fibrosis Associated with Experimental Fasciola hepatica Infection: Roles of Fas2 Proteinase and Hepatic Stellate Cell Activation (2011) (18)
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage (2020) (18)
Fully automated prediction of liver fibrosis using deep learning analysis of gadoxetic acid–enhanced MRI (2020) (18)
Elevated Expression of Tyrosine Kinase DDR2 in Primary Biliary Cirrhosis (2002) (18)
Autophagy and mesenchymal cell fibrogenesis. (2013) (18)
Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. (2006) (17)
Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma (2010) (16)
Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-101 (2005) (16)
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies (2021) (16)
KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. (2010) (15)
Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans (2019) (15)
Late intervention with the small molecule BB3 mitigates postischemic kidney injury. (2016) (15)
Stellate Cells and Hepatic Fibrosis (2015) (15)
Murine deficiency of peroxisomal l-bifunctional protein (EHHADH) causes medium-chain 3-hydroxydicarboxylic aciduria and perturbs hepatic cholesterol homeostasis (2021) (14)
Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C (2007) (14)
Acute Liver Injury and Decompensated Cirrhosis. (2020) (14)
SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (2018) (14)
Apolipoprotein E is secreted by cultured lipocytes of the rat liver. (1991) (14)
Cytochrome P 450 2 E 1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells * (2002) (13)
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification (2022) (13)
Targeting siRNA to arrest fibrosis (2008) (12)
Alcohol and inflammatory responses: summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meeting. (2015) (12)
Hepatic fibrosis: new insights into pathogenesis. (1990) (12)
Comparison of ADAPT, FIB4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR Screening Population. (2021) (12)
A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. (2010) (12)
Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. (2018) (11)
Induction and contribution of beta platelet‐derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice (2016) (11)
Dendritic cells in alcoholic liver injury and fibrosis. (2011) (11)
Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. (2021) (11)
Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin‐6 (2020) (10)
Risk Factors for Hepatocellular Carcinoma in Cirrhotic Patients with Chronic Hepatitis B. (2016) (10)
L59 TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice (2015) (10)
A candidate gene study for the association of host single nucleotide polymorphisms with liver cirrhosis risk in chinese hepatitis B patients. (2013) (10)
Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update (2021) (9)
Slit2‐Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells (2018) (9)
Gastrointestinal and hepatobiliary neoplasms in AIDS. (1988) (9)
“Cuts both ways”: Collagenases, lipocyte activation and polyunsaturated lecithin (1992) (9)
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications (2022) (8)
Parenchymal FE and collagen gene expression: An iron‐clad association? (1995) (8)
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative (2020) (7)
Chapter 6 – Hepatic Fibrosis and Cirrhosis (2006) (7)
Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors. (2008) (7)
Chapter 5 – Hepatic Fibrosis and Cirrhosis (2012) (7)
KLF 6-SV 1 overexpression accelerates human and mouse prostate cancer progression and metastasis (2018) (6)
Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ–Retinoid X Receptor α Coactivator (2018) (6)
Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395]. (2018) (6)
A Sabbatical: The Gift That Keeps on Giving (2018) (6)
Clarity and Challenges in Tissue Fibrosis (2015) (6)
The expression patterns and clinical significance of microRNAs in liver diseases and hepatocellular carcinoma. (2012) (6)
The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common? (2004) (6)
The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis (2021) (6)
255 ACTIVATION OF HEPATIC STELLATE CELLS FOLLOWING PHAGOCYTOSIS OF LYMPHOCYTES, A NOVEL PATHWAY OF FIBROGENESIS (2008) (6)
Scarring in alcoholic liver disease: new insights and emerging therapies. (1997) (5)
Platelets arrive at the scene of fibrosis……studies. (2011) (5)
Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C (2015) (5)
Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. (2019) (5)
Detection of a secreted metalloprotease within the nuclei of liver cells. (2011) (5)
Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis (2021) (5)
Vascular Injury Triggers Krüppel-Like Factor 6 (KLF6) Mobilization and Cooperation with Sp1 to Promote Endothelial Activation through Upregulation of the Activin Receptor-Like Kinase 1 (ALK1) Gene (2012) (5)
Fighting Cardiac Fibrosis with CAR T Cells. (2022) (5)
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver (2020) (5)
Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen (2021) (5)
Genetic characteristics of the human hepatic stellate cell line LX–2 (2012) (5)
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. (2016) (4)
Commentary: Gastroenterology and Hepatology: An Evolving Marriage, Not an Imminent Divorce (2009) (4)
Protect thee from the sins of thy fathers? (2012) (4)
Detection of intracellular ADAMTS13, a secreted zinc‐metalloprotease, via flow cytometry (2009) (4)
Phagocytosis of Apoptotic Bodies by Hepatic Stellate Cells Occurs in Vivo and Is an Important Mechanism in Liver Fibrogenesis (2005) (4)
Detection of novel biomarkers of liver cirrhosis by high performance proteomics (2009) (4)
The past 10 years of gastroenterology and hepatology—reflections and predictions (2014) (4)
Replacing a crystal ball with a calculator in predicting liver disease outcomes. (2014) (4)
Association of Genetic Variants With Rapid Fibrosis: Progression After Liver Transplantation for Hepatitis C (2014) (4)
Abdominal pregnancy. Diagnosis confirmed by hysterography (1937) (4)
Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model (2018) (4)
Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis (2021) (4)
Transporting pharmacogenomics into clinical practice. (2014) (4)
Activation of Hepatic Stellate Cells Requires Dissociation of E-Cadherin-Containing Adherens Junctions with Hepatocytes. (2020) (4)
Stellate Cells and Fibrosis (2020) (4)
Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury (2016) (3)
Excess iron into hepatocytes is required for activation of collagen I gene during experimental siderosis (1995) (3)
KLF6 promotes adipocyte differentiation through histone deacetylase 3 (HDAC3)-dependent repression of Dlk1 (2003) (3)
Devilish Effects of Taz in Nonalcoholic Steatohepatitis. (2016) (3)
Hepatic Stellate Cell-Immune Interactions in NASH (2022) (3)
The Immunopathogenesis of Cirrhosis (2014) (3)
Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development (2021) (3)
Focus. Metchnikoff, macrophages and the metabolic syndrome. (2012) (3)
Divergent roles of tumor suppressor gene Klf6 in ES cell differentiation (2008) (3)
Cellular and Molecular Pathobiology of Liver Fibrosis and its Pharmacological Intervention (2008) (3)
Chapter 9 – Molecular Mechanism of Stellate Cell Activation and Extracellular Matrix Remodeling (2003) (3)
357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study (2018) (3)
OE-258 Kruppel-like Factor 6 is a Key Transcription Factor That Controls Cardiac Fibrosis(Cardiac hypertrophy, basic/clinical(01)(M),Oral Presentation(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society) (2008) (3)
Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis (2021) (2)
Comprar The Biology of KrÃ¼ppel-like Factors | Nagai, Ryozo | 9784431877745 | Springer (2009) (2)
Focusing on the past, present, and future of hepatology. (2014) (2)
Abstract 16670: Anterior Myocardial Infarction and Low Ejection Fraction: Should We Anticoagulate? (2011) (2)
Fibrosis as a Major Mechanism of Chronic Liver Disease (2011) (2)
The role of kruppel-like factor 6 (KLF6) in colorectal neoplasia (2003) (2)
Genetic Characterization of Rat Hepatic Stellate Cell Line HSC-T6 for In Vitro Cell Line Authentication (2022) (2)
Downregulation of matrix and β-PDGF receptor gene expression by anti-TGFβ antibody in rat hepatic stellate cells during experimental liver injury (1997) (2)
24 A NOVEL MOLECULAR CLASSIFICATION OF HCV-RELATED HEPATOCELLULAR CARCINOMA (HCC) BASED ON INTEGRATIVE GENOMIC ANALYSIS (2008) (2)
Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitis (2020) (2)
Polymorphisms of AZIN1 rs2679757 and TRPM5 rs886277 are Associated with Cirrhosis Risk in Chinese Patients with Chronic Hepatitis B (2012) (2)
Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis (2021) (2)
Megatrends in bile acid receptor research (2017) (2)
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results (2017) (2)
A silent partner no longer – sinusoidal endothelial cells in liver homeostasis and disease. (2012) (2)
A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease (2018) (2)
Reply: To PMID 25865049. (2015) (2)
"There are decades where nothing happens; and there are weeks where decades happen"--Vladimir Ilyich Lenin. (2014) (2)
Mount Sinai Expert Guides: Hepatology: Hepatology (2014) (2)
Abstract 2996: Overexpression of potential oncogenic microRNAs defines a new molecular subclass of hepatocellular carcinoma (2010) (2)
Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion (2022) (2)
Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor (cid:2) –Retinoid X Receptor (cid:3) Coactivator (2018) (2)
S08ESBRA-NIAAA JOINT SYMPOSIUM ALCOHOLIC LIVER DISEASE: FROM PATHOGENESIS TO TREATMENTS08.1INCREASING BURDEN OF ALCOHOLIC LIVER DISEASE 2011 (2011) (2)
Krüppel-like Factors and the Liver (2009) (2)
Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. (2021) (2)
MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension (2022) (2)
Anti‐TNFα treatment in Crohn’s disease: Impact on hepatic steatosis, gut‐derived hormones and metabolic status (2021) (1)
[Polymorphism of ornithine decarboxylase antizyme inhibitor 1 gene is associated with liver cirrhosis in Chinese hepatitis B patients]. (2011) (1)
141 Anti-fibrotic activity of NK cells in experimental liver injury through enhanced activation combined with increased susceptibility of activated HSC's to killing (2003) (1)
Future Treatments: Antifibrotic Agents, Nitric Oxide Donors, and Gene Therapy in the Treatment of Portal Hypertension (2005) (1)
Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin (2007) (1)
Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation (2020) (1)
Hepatology at Mount Sinai: the present and the future. (2001) (1)
Chapter 6 – Liver fibrogenesis: Mechanisms and clinical relevance (2012) (1)
716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS (2012) (1)
A new human in vitro model to study early fibrogenesis. (2004) (1)
P0881 : Real world effectiveness and cost of simeprevir- and/or sofosbuvir-based HCV treatments: $175,000 per SVR12 (2015) (1)
Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878]. (2021) (1)
Antifibrotic targets and therapy in HCV (2005) (1)
1136 REGRESSION OF FIBROSIS AND REVERSAL OF CIRRHOSIS IN THIOACETAMIDE-INDUCED LIVER FIBROSIS FOLLOWING TREATMENT WITH GALECTIN INHIBITORS (2013) (1)
Publisher Correction: SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (2019) (1)
Nature, natural and NAFLD. (2011) (1)
94 KRÜPPEL-LIKE FACTOR 6 REGULATES PPAR ALPHA SIGNALING IN STEATOHEPATITIS VIA REPRESSION OF MIR-10B (2011) (1)
Final and future frontiers. (2014) (1)
507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data (2016) (1)
44 A multi-gene signature accurately predicts the risk of bridging fibrosis/cirrhosis in patients with chronic hepatitis C (2006) (1)
KLF6 (Kruppel like factor 6) (2011) (1)
The enlarging role of matrix metalloproteinases in liver injury – beyond scar degradation (2002) (1)
Perceptions of Hepatitis B among African Immigrants in New York City: An Opportunity to Increase Awareness and Avoid Stigma: 372 (2013) (1)
Synthesis of radiotracer for liver fibrosis (2001) (1)
Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma (2006) (1)
6. Hepatic Fibrogenesis (2011) (1)
Human Hepatic Stellate Cells Carry a New Splice Variant of the Human ADAMTS13 (2008) (0)
Identifying Patients With Nonalcoholic Steatohepatitis That Are Nonresponders to Therapy Reply (2016) (0)
Abstract #444: Molecular and clinical characterization of RICTOR (MTORC2) as a candidate oncogene in hepatocellular carcinoma (2009) (0)
Hepatic Fibrosis; Noninvasive Diagnostics and Treatment Strategies (2007) (0)
Technical aspects of genomics and proteomics in chronic liver disease (2012) (0)
Selected abstracts from the 9th CDD MRC Conference: Genes vs Environment in Cancer (2019) (0)
Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]. (2020) (0)
Survival of Neutrophils in Regulation of Bone Marrow Release and Central Role of Conventional Dendritic Cells (2014) (0)
CYP2E1-mediated oxidative stress induces COL1A2 mRNA in hepatic stellate cells and in a coculture system of HepG2 and stellate cells (1999) (0)
Introduction to the Symposium (1994) (0)
51 Novel growth suppressor targets of the KLF6 tumor suppressor gene identified by stringent microarray analysis (2003) (0)
HBV and HCV Screening of African Urban Populations in New York City with Linkage to Care by a Patient Navigator: A New Model for Viral Hepatitis Community Outreach Presidential Poster: 431 (2012) (0)
Additional file 2 Figure S2 (2013) (0)
Tracking HCC pathogenesis but not the tumor cells after biopsy. (2014) (0)
1274 MEF2 regulates hepatic stellate cell activation and growth (2003) (0)
Scarring in Alcoholic Liver Disease (1997) (0)
and activated hepatic stellate cells IL-10 receptor and coreceptor expression in quiescent (2005) (0)
Liver fibrogenesis: how to stop progression? (2009) (0)
266 Evidence of hedgehog signaling pathway activation in hepatocellular carcinoma (2006) (0)
Upregulation of Krüppel-Like Factor 6 is associated with acute liver injury in mice and humans (2015) (0)
First Amendment and "Foreign-Controlled" U.S. Corporations: Why Congress Ought to Affirm Domestic Subsidiaries' Corporate Political-Speech Rights (2013) (0)
RESPIR ATORY EDITORIAL BOARD (2015) (0)
Links from fibrosis to hepatocellular carcinoma (2013) (0)
KLF6 INTERACTS WITH FXR TARGET GENES AND EFFECTS THE OUTCOME OF PRIMARY SCLEROSING CHOLANGITIS (2019) (0)
NCytoskeleton of Liver Perisinusoidal Cells (Lipocytes) in Normal and Pathological Conditions (2004) (0)
Antifibrotic targets and therapy in HCV (2005) (0)
Sa1606 Effect of Liver Progenitor Cells on Hepatic Stellate Cells (2016) (0)
What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
Ergocalciferol significantly inhibits profibrogenic and proinflammatory gene expression by hepatic stellate cells: Ergocalciferol a potential supplement in the therapy of liver fibrosis (2010) (0)
Defining the genetic characteristics of human hepatic stellate cell line LX-2 by spectral karyotyping and short tandem repeat genotyping (2013) (0)
Abstract 4718: Potent preclinical antitumor effects induced by pan-histone deacetylase inhibitor panobinostat in combination with sorafenib in hepatocellular carcinoma (2012) (0)
DYSREGULATION OF TUMOR SUPPRESSOR KLF6 INCREASES HCC RELATED MORTALITY IN HCV INFECTED PATIENTS AND INCIDENCE OF TUMOR IN MOUSE MODEL OF HEPATIC CARCINOGENESIS (2009) (0)
β‐Catenin and HCC phenotype in mice and men (2013) (0)
Gene expression profiles of pre-neoplastic lesions and hepatocellular carcinoma in hepatitis C virus -cirrhotic patients (2005) (0)
current as in a JNK-Dependent Manner Receptor on Hepatic Stellate Cells β the TGF-Profibrotic Genes through Upregulation of IL-17 A Enhances the Expression of H . (2014) (0)
Development of novel radiotracer for liver fibrosis evalution (2001) (0)
SAT-234-Risk of hepatocellular carcinoma and efficacy of direct-acting antivirals in patients with concurrent hepatitis C virus (2019) (0)
Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural hematoma (2015) (0)
Liver-specific deletion of KLF6 uncovers novel transcriptional pathways linked to lipid and glucose homeostasis (2010) (0)
114 AUTOPHAGY: A NOVEL REGULATOR OF HEPATIC STELLATE CELL ACTIVATION AND FIBROGENESIS (2011) (0)
Acetylation status of KLF6 regulates its transactivation of p21 and may be a key determinant of hepatocellular growth (2001) (0)
Genome-wide transcriptome analysis identiﬁes novel gene signatures implicated in human chronic liver disease (2013) (0)
Commentary Kruppel Cripples Prostate Cancer KLF6 Progress and Prospects (2003) (0)
The peroxisomal transporter ABCD3 plays a major role in dicarboxylic fatty acid metabolism (2021) (0)
Receptor tyrosine kinase expression, a central component of rat hepatic stellate cell activation - characterization by homology PCR (1995) (0)
881 COMBINATION THERAPY WITH EGFR1–2/VEGFR INHIBITOR (XL647) AND SORAFENIB IMPROVES OUTCOMES IN A PRE-CLINICAL MODEL OF HCC (2010) (0)
Chapter 7 – Liver fibrogenesis: Mechanisms and clinical relevance (2017) (0)
379 Antifibrotic activity of refanlin, a hepatocyte growth factor analogue in vitro and in experimental liver fibrosis (2003) (0)
KLF6-SV1 accelerates prostate cancer progression and metastasis (2008) (0)
Artemisia capillaris Thunb. inhibits cell growth and induces apoptosis in human hepatic stellate cell line LX2 (2010) (0)
Abstract 15847: Kruppel-Like Factor 6 (KLF6) Regulates Obesity and Glucose Intolerance (2011) (0)
267 Key role of KLF6 in hepatocellular differentiation from embryonic stem cells (2003) (0)
MOLECULAR MECHANISMS OF HSC ACTIVATION AND ECM ACCUMULATION (2001) (0)
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models (2022) (0)
Preface to BBA issue devoted to fibrosis. (2013) (0)
Interleukin-15 Receptor α on Hepatic Stellate Cells Controls Fibrogenesis In Murine Liver Injury (2016) (0)
Principles on the path to a hepatologist's enlightenment (2015) (0)
Secreted folate receptor-gamma drives fibrogenesis in nonalcoholic steatohepatitis by amplifying TGFβ signaling in hepatic stellate cells (2022) (0)
Physical interaction between the kruppel-like transcriptional factors Zf9/KLF6 and GKLF/KLF4 and its effect on the human keratin 4 promoter (2000) (0)
Transcriptional Regulation by KLF6, A Novel Tumor Suppressor Gene in Prostate Cancer, Through Interaction with HATS and HDACS (2006) (0)
Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular Carcinoma (2008) (0)
Development and Validation of a Non-Invasive Model for Predicting Fibrosis Resolution One Year after Lifestyle Intervention for Biopsy-Proven Non-Alcoholic Steatohepatitis (2016) (0)
END-STAGE LIVER DISEASE Bone marrow suppression Deteriorated liver function Portal hypertension TPO Splenic sequestration Plasma expansion Platelet production Platelet destruction Thrombocytopenia with platelets in liver FIBROGENESIS (2011) (0)
TGF-β regulates expression of KLF6 and its splice variants, and promotes cooperative transactivation of common target genes through a Smad3/Sp1/KLF6 interaction (2009) (0)
[202] SELECTIVE LONG-TERM ACTIVATION OF CANNABINOID CB RECEPTORS REDUCES HEPATIC FIBROSIS IN CIRRHOTIC RATS WITH ASCITES (2007) (0)
Role of hepatic stellate cells in liver tumor angiogenesis (2002) (0)
Performance of native and gadoxetate-enhanced liver and spleen T1 mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results (2022) (0)
110 MOLECULAR AND CLINICAL CHARACTERIZATION OF RICTOR (MTORC2) AS A CANDIDATE ONCOGENE IN HEPATOCELLULAR CARCINOMA (2009) (0)
Genome-wide identification of miRNA binding-sites in primary human hepatic stellate cells IL-1 signaling regulates bile duct injury and obstruction in biliary atresia (2014) (0)
211: OUTCOMES IN INFANTS BORN TO MOTHERS WITH AND WITHOUT NON-ALCOHOLIC FATTY LIVER DISEASE (2022) (0)
Prostaglandin E-2 inhibits transforming growth factor-beta-induced collagen A1(I) gene expression in human hepatic stellate cells; Implications for use of COX-2 inhibitors in patients with hepatic fibrosis (2002) (0)
The future of hepatology: Embrace change (2015) (0)
Autophagy regulates endothelial dysfunction and hepatic fibrosis development (2017) (0)
Early identification of patients with acute myocardial infarction: The utility of a new rapid quantitative assay for serum myoglobin (1994) (0)
P1301 : A novel role for krüppel-like-factor 6 in hepatic regeneration and acute liver failure (2015) (0)
Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis (2017) (0)
Cell Death and Autophagy in Hepatic Stellate Cell Activation and Function (2017) (0)
Activin Receptor-Like Kinase 1 Gene Specificity Protein 1 to Promote Endothelial Activation Through Upregulation of the Vascular Injury Triggers Krüppel-Like Factor 6 Mobilization and Cooperation With (2012) (0)
Regression of Fibrosis Following Hepatitis C Eradication. (2022) (0)
University of Groningen Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury (2017) (0)
66 SERUM LEVELS OF THE PRO-INFLAMMATORY CYTOKINE HMGB1 CORRELATE WITH VAGUS NERVE ACTIVITY. (2004) (0)
915 INTRIGUING RELATIONSHIP BETWEEN VITAMIN D AND LIVER FIBROSIS (2010) (0)
Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury (2019) (0)
A Decade of Model for End-Stage Liver Disease (MELD): Is it Time to Uncap the MELD? Initial Single-Center Experience in the United States with Early Liver Transplantation for Severe Alcoholic Hepatitis (2013) (0)
Hepatocyte KLF6 regulates autophagy in a p53 dependent manner (2016) (0)
Reply: (2005) (0)
Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye. (2007) (0)
Signaling and Regulation Hepatocyte Growth Factor Enhances Alternative Splicing of the Kr € uppel-like Factor 6 ( KLF 6 ) Tumor Suppressor to Promote Growth Though SRSF (2012) (0)
216 Targeted and regulable expression of transgenes in hepatic stellate cells using an adenoviral CRE-loxp system (2003) (0)
Abstract P-542: HEAT STRESS INDUCED PERI-MYOCARDITIS DUE TO A NOVEL MUTATION IN HIKESHI NUCLEAR IMPORT CARRIER OF HEAT SHOCK PROTEIN 70 (2018) (0)
Nogo-B (Reticulon B) in Kupffer cells promotes alco- hol-induced hepatic steatosis (2014) (0)
Transcription factor KLF6 upregulates gene expression of metaloprotease MMP-14 and soluble endoglin release upon vascular injury (2015) (0)
OL-085 A candidate genes study for the association of host single nucleotide polymorphisms with liver cirrhosis risk in Chinese hepatitis B patients (2011) (0)
Additional file 1 Figure S1 (2013) (0)
Characterisation of hepatic lipocyte type IV collagenase/gelatinase (1989) (0)
ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Transplantation Trends in Primary Biliary Cirrhosis (2007) (0)
Reply (2016) (0)
371 ENDOPLASMIC RETICULUM STRESS ACTIVATES HEPATIC STELLATE CELLS THROUGH AUTOPHAGIC SIGNALING (2012) (0)
Integrin Alpha 11 Significance in Phenotypic Transformation of Hepatic Stellate Cells in Liver Fibrosis (2016) (0)
Sterilization of contaminated burrs. (1994) (0)
Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice (2021) (0)
FORMES ALTERNATIVES D'EPISSURE DE KLF6 ET POLYMORPHISME D'ADN DE KLF6 DE CELLULES GERMINALES ASSOCIES A UN RISQUE ACCRU DE CANCER (2005) (0)
Hepatitis C virus infected apoptotic cells (bodies) differentially activate hepatic Stellate cells as compared to non-infected apoptotic bodies (2006) (0)
KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION. (2003) (0)
Inhibition of P53-mediated apoptosis by BCL-XL endogenously expressed in human hepatocellular carcinoma (2000) (0)
Thomas D. Boyer, MD (1943-2018). (2018) (0)
HSC Activation and Retinoid Metabolism (2001) (0)
A physician-scientist’s wish list for the 2016 U.S. presidential candidates (2016) (0)
Abstract 18872: Kruppel-like Factor 6 Promotes Obesity and Glucose Intolerance Through Adipocyte Differentiation (2012) (0)
A single nucleotide polymorphism of DDX5 that confers more rapid fibrosis progression is associated with reduced transcriptional repression of key fibrogenic genes in hepatic stellate cells (2008) (0)
Prospective Comparison of IVIM DWI, MR Elastography and Transient Elastography for the detection of liver fibrosis in HCV. Initial results (2012) (0)
P0990 : Non-alcoholic steatohepatitis is an independent predictor of mortality in a cohort of 493 morbidly obese patients undergoing bariatric surgery (2015) (0)
Focus. An emerging conceptual scaffold for NASH. (2012) (0)

This paper list is powered by the following services:

Other Resources About Scott L. Friedman

en.wikipedia.org

What Schools Are Affiliated With Scott L. Friedman?

Scott L. Friedman is affiliated with the following schools:

Image Attributions

Image Source for Scott L. Friedman